List of Figures
Figure 1: Global Viral Vector and Plasmid Manufacturing Market (by Region), 2019 and 2030
Figure 2: Key Players of the Global Viral Vector and Plasmid Manufacturing Market
Figure 3: Drivers, Challenges, and Opportunities of the Global Viral Vector and Plasmid Manufacturing Market
Figure 4: Share of Key Developments and Strategies, January 2017-February 2020
Figure 5: Global Viral Vector and Plasmid Manufacturing Market (by Vector Type), 2019 and 2030
Figure 6: Global Viral Vector and Plasmid Manufacturing Market (by Viral Vector), 2019 and 2030
Figure 7: Global Viral Vector and Plasmid Manufacturing Market (by Disease), 2019 and 2030
Figure 8: Global Viral Vector and Plasmid Manufacturing Market (by Application), 2019 and 2030
Figure 2.1: Global Viral Vector and Plasmid Manufacturing Market Segmentation
Figure 3.1: Global Viral Vector and Plasmid Manufacturing Market Research Methodology
Figure 3.2: Primary Research
Figure 3.3: Secondary Research
Figure 3.4: Data Triangulation
Figure 3.5: Bottom-up Approach (Segment-Wise Analysis)
Figure 3.6: Top-Down Approach (Segment-Wise Analysis)
Figure 3.7: Assumptions and Limitations
Figure 4.1: Mechanism of Action of Vectors
Figure 4.2: Evolutionary History of Vectors
Figure 4.3: Typical Production Methods of Viral Vectors and Plasmids
Figure 4.4: Global Viral Vector and Plasmid Manufacturing Market, 2019-2030
Figure 5.1: Drivers, Challenges, and Opportunities of the Global Viral Vector and Plasmid Manufacturing Market
Figure 5.2: Estimated New Cancer Cases and Deaths (by Sex), U.S., 2020
Figure 6.1: Workflow Associated With Biomanufacturing
Figure 6.2: Global Viral Vector and Plasmid Manufacturing Market: Patent Analysis (by Year of Publication), June 2017-December 2019
Figure 7.1: Competitive Landscape, January 2017- March 2020
Figure 7.2: Share of Key Developments and Strategies, January 2017-February 2020
Figure 7.3: Partnerships and Alliances (by Company), January 2017-February 2020
Figure 7.4: Business Expansions (by Company), January 2017-February 2020
Figure 7.5: New Offerings (by Company), January 2017-February 2020
Figure 7.6: M&A Activities (by Company), January 2017-February 2020
Figure 7.7: Others (by Company), January 2017-February 2020
Figure 7.8: Market Share Analysis of Global Viral Vector and Plasmid Manufacturing Market, 2019
Figure 8.1: Global Viral Vector and Plasmid Manufacturing Market Segmentation (by Vector)
Figure 8.2: Global Viral Vector and Plasmid Manufacturing Market (by Vector Type), 2019 and 2030
Figure 8.3: Global Viral Vector and Plasmid Manufacturing Market for Viral Vectors, 2019-2030
Figure 8.4: Global Viral Vector and Plasmid Manufacturing Market (by Viral Vector), 2019 and 2030
Figure 8.5: Global Viral Vector and Plasmid Manufacturing Market for Adenoviral Vectors, 2019-2030
Figure 8.6: Global Viral Vector and Plasmid Manufacturing Market for Retroviral Vectors, 2019-2030
Figure 8.7: Global Viral Vector and Plasmid Manufacturing Market for Adeno-Associated Viral Vectors, 2019-2030
Figure 8.8: Global Viral Vector and Plasmid Manufacturing Market for Lentiviral Vectors, 2019-2030
Figure 8.9: Global Viral Vector and Plasmid Manufacturing Market for Vaccinia Viral Vectors, 2019-2030
Figure 8.10: Global Viral Vector and Plasmid Manufacturing Market for Other Viral Vectors, 2019-2030
Figure 8.11: Global Viral Vector and Plasmid Manufacturing Market for Viral Vectors, 2019-2030
Figure 9.1: Global Viral Vector and Plasmid Manufacturing Market Segmentation (by Disease)
Figure 9.2: Global Viral Vector and Plasmid Manufacturing Market (by Disease), 2019 and 2030
Figure 9.3: Global Viral Vector and Plasmid Manufacturing Market for Cancer, 2019-2030
Figure 9.4: List of Monogenic Disorders for which Human Gene Transfer Trials Have Been Approved
Figure 9.5: Global Viral Vector and Plasmid Manufacturing Market for Genetic Diseases, 2019-2030
Figure 9.6: Global Viral Vector and Plasmid Manufacturing Market for Infectious Diseases, 2019-2030
Figure 9.7: Global Viral Vector and Plasmid Manufacturing Market for Infectious Diseases, 2019-2030
Figure 9.8: Global Viral Vector and Plasmid Manufacturing Market for Other Diseases, 2019-2030
Figure 10.1: Global Viral Vector and Plasmid Manufacturing Market Segmentation (by Application)
Figure 10.2: Global Viral Vector and Plasmid Manufacturing Market (by Application), 2019 and 2030
Figure 10.3: Global Viral Vector and Plasmid Manufacturing Market for Gene Therapy, 2019-2030
Figure 10.4: Global Viral Vector and Plasmid Manufacturing Market for Vaccinology, 2019-2030
Figure 10.5: Global Viral Vector and Plasmid Manufacturing Market for Cell Therapy, 2019-2030
Figure 10.6: Global Viral Vector and Plasmid Manufacturing Market for Cell Therapy, 2019-2030
Figure 11.1: Global Viral Vector and Plasmid Manufacturing Market (by Region), 2019 and 2030
Figure 11.2: North America: Viral Vector and Plasmid Manufacturing Market, 2019-2030
Figure 11.3: North America: Market Dynamics
Figure 11.4: North America: Viral Vector and Plasmid Manufacturing Market (by Country), 2019 and 2030
Figure 11.5: U.S.: Viral Vector and Plasmid Manufacturing Market, 2019-2030
Figure 11.6: Canada: Viral Vector and Plasmid Manufacturing Market, 2019-2030
Figure 11.7: Europe: Viral Vector and Plasmid Manufacturing Market, 2019-2030
Figure 11.8: Europe: Market Dynamics
Figure 11.9: Europe: Viral Vector and Plasmid Manufacturing Market (by Country), 2019 and 2030
Figure 11.10: Germany: Viral Vector and Plasmid Manufacturing Market, 2019-2030
Figure 11.11: U.K.: Viral Vector and Plasmid Manufacturing Market, 2019-2030
Figure 11.12: France: Viral Vector and Plasmid Manufacturing Market, 2019-2030
Figure 11.13: Italy: Viral Vector and Plasmid Manufacturing Market, 2019-2030
Figure 11.14: Switzerland: Viral Vector and Plasmid Manufacturing Market, 2019-2030
Figure 11.15: Belgium: Viral Vector and Plasmid Manufacturing Market, 2019-2030
Figure 11.16: Spain: Viral Vector and Plasmid Manufacturing Market, 2019-2030
Figure 11.17: Rest-of-Europe: Viral Vector and Plasmid Manufacturing Market, 2019-2030
Figure 11.18: Asia-Pacific: Viral Vector and Plasmid Manufacturing Market, 2019-2030
Figure 11.19: Asia-Pacific: Market Dynamics
Figure 11.20: Asia-Pacific: Viral Vector and Plasmid Manufacturing Market (by Country), 2019 and 2030
Figure 11.21: China: Viral Vector and Plasmid Manufacturing Market, 2019-2030
Figure 11.22: Australia: Viral Vector and Plasmid Manufacturing Market, 2019-2030
Figure 11.23: Japan: Viral Vector and Plasmid Manufacturing Market, 2019-2030
Figure 11.24: India: Viral Vector and Plasmid Manufacturing Market, 2019-2030
Figure 11.25: South Korea: Viral Vector and Plasmid Manufacturing Market, 2019-2030
Figure 11.26: Singapore: Viral Vector and Plasmid Manufacturing Market, 2019-2030
Figure 11.27: Rest-of-Asia-Pacific: Viral Vector and Plasmid Manufacturing Market, 2019-2030
Figure 11.28: Rest-of-the-World: Viral Vector and Plasmid Manufacturing Market, 2019-2030
Figure 11.29: Rest-of-the-World: Viral Vector and Plasmid Manufacturing Market (Latin America and Middle-East and Africa), 2019-2030
Figure 12.1: Shares of Key Company Profiles
Figure 12.2: Aldevron, LLC: Service / Product Portfolio for Global Viral Vector and Plasmid Manufacturing Market
Figure 12.3: Aldevron, LLC: SWOT Analysis
Figure 12.4: Boehringer Ingelheim: Product Portfolio for the Global Viral Vector and Plasmid Manufacturing Market
Figure 12.5: Boehringer Ingelheim: SWOT Analysis
Figure 12.6: Catalent, Inc: Service / Product Portfolio for Global Viral Vector and Plasmid Manufacturing Market
Figure 12.7: Catalent, Inc: Overall Financials, 2017-2019
Figure 12.8: Catalent, Inc.: Net Revenue (by Business Segment), 2017-2019
Figure 12.9: Catalent, Inc.: Net Revenue (by Region), 2017-2019
Figure 12.10: Catalent, Inc.: R&D Expense, 2017-2019
Figure 12.11: Catalent, Inc.: SWOT Analysis
Figure 12.12: FUJIFILM Holdings Corporation: Service / Product Portfolio for the Global Viral Vector and Plasmid Manufacturing Market
Figure 12.13: FUJIFILM Holdings Corporation: Overall Financials, 2017-2019
Figure 12.14: FUJIFILM Holdings Corporation: Net Revenue (by Business Segment), 2017-2019
Figure 12.15: FUJIFILM Holdings Corporation: Healthcare and Material Solutions Revenue (by Sub-Segment), 2017-2019
Figure 12.16: FUJIFILM Holdings Corporation: R&D Expense, 2017-2019
Figure 12.17: FUJIFILM Holdings Corporation: SWOT Analysis
Figure 12.18: GE Healthcare: Service / Product Portfolio for the Global Viral Vector and Plasmid Manufacturing Market
Figure 12.19: GENERAL ELECTRIC Company: Overall Financials, 2017-2019
Figure 12.20: GENERAL ELECTERIC: Revenue (by Business Model), 2017-2019
Figure 12.21: GENERAL ELECTRIC: Revenue (by Region), 2017-2019
Figure 12.22: GENERAL ELECTRIC: R&D Expenditure, 2017-2019
Figure 12.23: GENERAL ELECTRIC: SWOT Analysis
Figure 12.24: GenScript: Service / Product Portfolio for the Global Viral Vector and Plasmid Manufacturing Market
Figure 12.25: GenScript: Overall Financials, 2016-2018
Figure 12.26: GenScript: R&D Expense, 2016-2018
Figure 12.27: GenScript: SWOT Analysis
Figure 12.28: Lonza: Service / Product Portfolio for Global Viral Vector and Plasmid Manufacturing Market
Figure 12.29: Lonza: Overall Financials, 2017-2019
Figure 12.30: Lonza: Revenue (by Segment), 2017-2019
Figure 12.31: Lonza: Revenue (by Region), 2017-2019
Figure 12.32: Lonza: R&D Expenditure (2017-2019)
Figure 12.33: Lonza: SWOT Analysis
Figure 12.35: Merck KGaA: Overall Financials, 2017-2019
Figure 12.36: Merck KGaA: Revenue (by Product and Services), 2017-2019
Figure 12.37: Merck KGaA: Revenue (by Region), 2017-2019
Figure 12.38: Merck KGaA: R&D Expenditure, 2017-2019
Figure 12.40: MolMed S.p.A.: Service / Product Portfolio for the Global Viral Vector and Plasmid Manufacturing Market
Figure 12.41: MolMed S.p.A.: Overall Financials, 2016-2018
Figure 12.42: MolMed S.p.A.: SWOT Analysis
Figure 12.43: Novasep Holding SAS: Service / Product Portfolio for the Global Viral Vector and Plasmid Manufacturing Market
Figure 12.44: Novasep Holding SAS: SWOT Analysis
Figure 12.45: Oxford Biomedica plc: Service / Product Portfolio for Global Viral Vector and Plasmid Manufacturing Market
Figure 12.46: Oxford Biomedica plc: Overall Financials, 2016-2018
Figure 12.47: Oxford Biomedica plc: Revenue (by Segment), 2016-2018
Figure 12.48: Oxford Biomedica plc: R&D Expenditure (2016-2018)
Figure 12.49: Oxford Biomedica plc: SWOT Analysis
Figure 12.50: Sartorius AG: Service/Product Portfolio for the Global Viral Vector and Plasmid Manufacturing Market
Figure 12.51: Sartorius AG: Overall Financials, 2017-2019
Figure 12.52: Sartorius AG: Revenue (by Business Segment), 2017-2019
Figure 12.53: Sartorius AG: Revenue (by Region), 2017-2019
Figure 12.54: Sartorius AG: R&D Expenditure (2017-2019)
Figure 12.55: Sartorius AG: SWOT Analysis
Figure 12.56: Takara Bio Inc.: Service/Product Portfolio for the Global Viral Vector and Plasmid Manufacturing Market
Figure 12.57: Takara Bio Inc.: Overall Financials, 2017-2019
Figure 12.58: Takara Bio Inc.: Revenue (by Business Segment), 2017-2019
Figure 12.59: Takara Bio Inc.: Revenue (by Region), 2017-2019
Figure 12.60: Takara Bio Inc.: R&D Expenditure (2017-2019)
Figure 12.61: Takara Bio Inc.: SWOT Analysis
Figure 12.62: Thermo Fisher Scientific, Inc.: Service / Product Portfolio for the Global Viral Vector and Plasmid Manufacturing Market
Figure 12.63: Thermo Fisher Scientific, Inc.: Overall Financials, 2017-2019
Figure 12.64: Thermo Fisher Scientific, Inc.: Revenue (by Business Segment), 2017-2019
Figure 12.65: Thermo Fisher Scientific, Inc.: Revenue (by Region), 2017-2019
Figure 12.66: Thermo Fisher Scientific, Inc.: R&D Expenditure (2017-2019)
Figure 12.67: Thermo Fisher Scientific, Inc.: SWOT Analysis
Figure 12.68: WuXi AppTec: Service / Product Portfolio for the Global Viral Vector and Plasmid Manufacturing Market
Figure 12.69: WuXi AppTec: Overall Financials, 2016-2018
Figure 12.70: WuXi AppTec: Net Revenue (by Business Segment), 2016-2018
Figure 12.71: WuXi AppTec: Net Revenue (by Region), 2016-2018
Figure 12.72: WuXi AppTec: R&D Expense, 2016-2018
Figure 12.73: WuXi AppTec: SWOT Analysis